Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Oxford BioMedica halted TroVax injections

Conditions

Prostatic Neoplasms

Interventions

BIOLOGICAL: MVA 5T4
DRUG: Docetaxel

Sponsor

The Methodist Hospital Research Institute

Collaborators

[object Object]